CL2012003094A1 - Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer. - Google Patents

Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.

Info

Publication number
CL2012003094A1
CL2012003094A1 CL2012003094A CL2012003094A CL2012003094A1 CL 2012003094 A1 CL2012003094 A1 CL 2012003094A1 CL 2012003094 A CL2012003094 A CL 2012003094A CL 2012003094 A CL2012003094 A CL 2012003094A CL 2012003094 A1 CL2012003094 A1 CL 2012003094A1
Authority
CL
Chile
Prior art keywords
lrp6
nucleic acid
antibody
bivalent
grouping
Prior art date
Application number
CL2012003094A
Other languages
English (en)
Inventor
Ettenberg Seth
Cong Feng
Hartlepp Felix
Klagge Ingo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44227756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012003094A1 publication Critical patent/CL2012003094A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actúa sobre LRP6 potenciando una señal Wnt al agrupar uno o más receptores LRP6 en presencia de una proteína de unión de LRP6; ácido nucleico que lo codifica; vector que comprende dicho ácido nucleico; composición farmacéutica que comprende un anticuerpo multivalente anti-LRP6; y su uso para tratar cáncer.
CL2012003094A 2010-05-06 2012-11-06 Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer. CL2012003094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33198510P 2010-05-06 2010-05-06

Publications (1)

Publication Number Publication Date
CL2012003094A1 true CL2012003094A1 (es) 2013-03-22

Family

ID=44227756

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2012003094A CL2012003094A1 (es) 2010-05-06 2012-11-06 Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.
CL2014000177A CL2014000177A1 (es) 2010-05-06 2014-01-23 Anticuerpo bivalente aislado que actua sobre una proteina relacionada con lipoproteinas de baja densidad (lrp6); acido nucleico y vector que codifican dicho anticuerpo; uso para tratar cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2014000177A CL2014000177A1 (es) 2010-05-06 2014-01-23 Anticuerpo bivalente aislado que actua sobre una proteina relacionada con lipoproteinas de baja densidad (lrp6); acido nucleico y vector que codifican dicho anticuerpo; uso para tratar cancer.

Country Status (22)

Country Link
US (3) US9428583B2 (es)
EP (3) EP4234698A3 (es)
JP (5) JP2013527762A (es)
KR (1) KR20130066632A (es)
CN (1) CN103038258B (es)
AU (2) AU2011249783B9 (es)
BR (1) BR112012028306A2 (es)
CA (1) CA2798432A1 (es)
CL (2) CL2012003094A1 (es)
CO (1) CO6630181A2 (es)
EA (1) EA201291180A1 (es)
ES (2) ES2659406T3 (es)
GT (1) GT201200297A (es)
HK (1) HK1258029A1 (es)
IL (1) IL222811A0 (es)
MX (1) MX2012012928A (es)
NZ (1) NZ603829A (es)
PE (1) PE20130207A1 (es)
SG (1) SG185416A1 (es)
TN (1) TN2012000511A1 (es)
WO (1) WO2011138392A1 (es)
ZA (1) ZA201208221B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2567709T3 (pl) * 2007-11-02 2018-06-29 Novartis Ag Cząsteczki i sposoby modulowania białka związanego z receptorem dla lipoproteiny o niskiej gęstości 6 (LRP6)
SG184033A1 (en) 2010-03-24 2012-10-30 Genentech Inc Anti-lrp6 antibodies
EP2566894A1 (en) * 2010-05-06 2013-03-13 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
TW201323442A (zh) * 2011-11-04 2013-06-16 Novartis Ag 低密度脂蛋白相關蛋白６（ｌｒｐ６）－半衰期延長構築體
JP6655074B2 (ja) * 2014-06-20 2020-02-26 ジェネンテック， インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
WO2016040895A1 (en) 2014-09-12 2016-03-17 xxTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Wnt signaling agonist molecules
LT3383425T (lt) 2015-12-04 2020-10-12 Boehringer Ingelheim International Gmbh Biparatopiniai polipeptidai, veikiantys antagonistiškai wnt signaliniam keliui vėžinėse ląstelėse
CN107029211A (zh) * 2017-05-05 2017-08-11 上海市东方医院（同济大学附属东方医院） 一种用于治疗心衰保护心脏功能的药物
AU2018276409A1 (en) * 2017-05-31 2019-10-31 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
AU2018393076A1 (en) * 2017-12-19 2020-07-02 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
JP7330977B2 (ja) 2017-12-19 2023-08-22 スロゼン オペレーティング， インコーポレイテッド Ｗｎｔサロゲート分子及びその使用
US11578129B2 (en) 2019-03-29 2023-02-14 Boehringer Ingelheim International Gmbh LRP5 and PD-1 antagonist anticancer combination therapy
US20200308276A1 (en) * 2019-03-29 2020-10-01 Boehringer Ingelheim International Gmbh Anticancer combination therapy
AU2020327000A1 (en) * 2019-08-08 2022-03-31 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
CA3147832A1 (en) * 2019-08-14 2021-02-18 Sachdev S. Sidhu Antibodies that bind to lrp6 proteins and methods of use
WO2023147293A2 (en) * 2022-01-25 2023-08-03 The Trustees Of The University Of Pennsylvania Compositions and methods comprising anti-cd38 chimeric antigen receptors (cars)

Family Cites Families (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2207308A (en) 1940-07-09 Electrolytic manufacture
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE3813023A1 (de) 1988-04-19 1989-11-16 Behringwerke Ag Monoklonaler antikoerper gegen pseudomonas aeruginosa, seine herstellung und verwendung
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
EP0550436A1 (en) 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5242813A (en) 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
KR100246529B1 (ko) 1990-12-14 2000-04-01 스티븐 에이. 서윈. 엠.디. 수용체 관련된 신호 변환 경로를 위한 키메라 사슬
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
DE69233408T2 (de) 1991-12-02 2005-09-22 Cambridge Antibody Technology Ltd., Melbourn Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
AU3665893A (en) 1992-02-12 1993-09-03 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Sequences characteristic of human gene transcription product
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
NZ292124A (en) 1994-07-29 1998-10-28 Smithkline Beecham Plc Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
JP2000507912A (ja) 1995-08-31 2000-06-27 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 作用剤の徐放性組成物
WO1997032572A2 (en) 1996-03-04 1997-09-12 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
PT954282E (pt) 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4271735B2 (ja) 1997-04-15 2009-06-03 メルク アンド カンパニー，インコーポレイティド 新規のｌｄｌ−レセプター
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
AU729035B2 (en) 1997-06-12 2001-01-25 Novartis Ag Artificial antibody polypeptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US6780609B1 (en) 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
WO2000008181A2 (en) 1998-08-07 2000-02-17 Onyx Pharmaceuticals, Inc. Chp polypeptide, a ligand of pak65
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
AU2416600A (en) 1999-01-20 2000-08-07 Rigel Pharmaceuticals, Inc. Exocytosis pathway proteins and methods of use
WO2000052165A2 (en) 1999-03-04 2000-09-08 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
EP1396543A3 (en) 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DK1144607T5 (da) 1999-07-20 2009-10-05 Morphosys Ag Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US20030138804A1 (en) 2000-02-03 2003-07-24 Boyle Bryan J. Methods and materials relating to novel C-type lectin receptor-like polypeptides and polynucleotides
WO2001079442A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
EP1328626B1 (en) 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
JP2005511002A (ja) 2001-05-11 2005-04-28 ワイス 骨量変調のトランスジェニック動物モデル
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
JP2005512508A (ja) 2001-05-17 2005-05-12 ゲノム　セラピューティックス　コーポレーション Ｄｋｋ媒介性相互作用を変調する試薬および方法
JP2004532038A (ja) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
JP4199662B2 (ja) 2001-09-13 2008-12-17 財団法人化学及血清療法研究所 新規なセレノシステイン含有タンパク質
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US20030157579A1 (en) 2002-02-14 2003-08-21 Kalobios, Inc. Molecular sensors activated by disinhibition
US7335478B2 (en) 2002-04-18 2008-02-26 Kalobios Pharmaceuticals, Inc. Reactivation-based molecular interaction sensors
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US20030194708A1 (en) 2002-04-10 2003-10-16 Minke Binnerts Human homolog of crossveinless materials and methods
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
EP2316852B1 (en) 2002-11-08 2014-03-05 Ablynx N.V. Stabilized single domain antibodies
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
US20070020497A1 (en) 2003-05-07 2007-01-25 Gs Yuasa Corporation Direct fuel cell system
WO2004101790A1 (en) 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
US20050084494A1 (en) 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US8637506B2 (en) 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US20080227734A1 (en) 2003-11-24 2008-09-18 Gunnar Westin Mutant Lrp5/6 Wnt-Signaling Receptors in Cancer Diagnosis, Prognosis, and Treatment
EP1761561B1 (en) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US20060094046A1 (en) 2004-02-11 2006-05-04 Arie Abo Compositions and methods relating to angiogenesis and tumorigenesis
US20060127919A1 (en) 2004-02-25 2006-06-15 Arie Abo Compositions and methods relating to cell adhesion molecule L1
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
US7684505B2 (en) 2004-04-26 2010-03-23 Qualcomm Incorporated Method and apparatus for encoding interleaving and mapping data to facilitate GBPS data rates in wireless systems
CN1981054A (zh) 2004-05-14 2007-06-13 加利福尼亚大学董事会 用抗wnt2单克隆抗体和sirna治疗癌症的方法
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
US8809287B2 (en) 2004-11-15 2014-08-19 Icahn School Of Medicine At Mount Sinai Compositions and methods for altering Wnt autocrine signaling
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7838252B2 (en) 2005-02-17 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject having an anthrax toxin mediated condition
MY169746A (en) 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
AU2006287416A1 (en) 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
MX2008014722A (es) 2006-05-19 2011-04-15 Teva Pharma Proteinas de fusion, usos de las mismas y procesos para producir las mismas.
US7563619B2 (en) 2006-05-30 2009-07-21 Van Andel Research Institute Mammary stem cell marker
US20100129928A1 (en) 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
WO2008027739A2 (en) 2006-08-28 2008-03-06 Nuvelo, Inc. Antibodies to ntb-a
JP2010526090A (ja) * 2007-04-30 2010-07-29 ワシントン・ユニバーシティ 癌の治療のための方法および組成物
JP2010527936A (ja) 2007-05-18 2010-08-19 メディミューン，エルエルシー 炎症性疾患におけるｉｌ−３３
EP2222846B1 (en) 2007-08-10 2017-05-03 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
US20090155255A1 (en) 2007-09-27 2009-06-18 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
WO2009051957A2 (en) 2007-10-16 2009-04-23 Nuvelo, Inc. Antibodies to irem-1
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
PL2567709T3 (pl) 2007-11-02 2018-06-29 Novartis Ag Cząsteczki i sposoby modulowania białka związanego z receptorem dla lipoproteiny o niskiej gęstości 6 (LRP6)
AU2008320987B2 (en) 2007-11-13 2014-04-17 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against TL1A
WO2009064944A2 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
AU2009234253C1 (en) 2008-04-11 2015-05-07 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
RU2483081C2 (ru) 2008-07-23 2013-05-27 Ханми Сайенс Ко.,Лтд.,Kr Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
JP5693475B2 (ja) 2009-03-04 2015-04-01 ペイタント・ソリューションズ・インコーポレイテッドＰｅｙｔａｎｔ Ｓｏｌｕｔｉｏｎｓ， Ｉｎｃ． 羊膜組織を含む材料で修飾されたステント及び対応する方法
US8524869B2 (en) 2009-03-24 2013-09-03 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against LIGHT and uses thereof
CN102458442B (zh) 2009-04-08 2016-06-29 加利福尼亚大学董事会 具有受控血清药代动力学的人蛋白支架
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US20110023351A1 (en) 2009-07-31 2011-02-03 Exxonmobil Research And Engineering Company Biodiesel and biodiesel blend fuels
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
AU2010306774A1 (en) 2009-10-14 2012-05-03 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
JP6050124B2 (ja) * 2010-02-19 2016-12-21 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ Ｗｎｔシグナル伝達経路を阻害するモノクローナル抗体ならびにその製造方法およびその使用方法
WO2011106707A2 (en) 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
SG184033A1 (en) * 2010-03-24 2012-10-30 Genentech Inc Anti-lrp6 antibodies
EP2566894A1 (en) 2010-05-06 2013-03-13 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2012175741A2 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012054565A1 (en) 2010-10-20 2012-04-26 Genentech, Inc. Methods and compositions for modulating the wnt pathway
US20140017264A1 (en) 2010-12-10 2014-01-16 Merrimack Pharmaceuticals, Inc. Dosage and administration of bispecific scfv conjugates
TW201323442A (zh) 2011-11-04 2013-06-16 Novartis Ag 低密度脂蛋白相關蛋白６（ｌｒｐ６）－半衰期延長構築體

Also Published As

Publication number Publication date
EP3345926A1 (en) 2018-07-11
AU2011249783B9 (en) 2014-11-06
JP2022137092A (ja) 2022-09-21
CL2014000177A1 (es) 2014-08-08
US20170362326A1 (en) 2017-12-21
WO2011138392A1 (en) 2011-11-10
JP2017008060A (ja) 2017-01-12
CO6630181A2 (es) 2013-03-01
EA201291180A1 (ru) 2013-05-30
US20130058934A1 (en) 2013-03-07
TN2012000511A1 (en) 2014-04-01
EP2566892A1 (en) 2013-03-13
AU2011249783B2 (en) 2014-10-09
AU2011249783A1 (en) 2012-12-20
PE20130207A1 (es) 2013-02-28
EP4234698A2 (en) 2023-08-30
KR20130066632A (ko) 2013-06-20
IL222811A0 (en) 2012-12-31
ES2659406T3 (es) 2018-03-15
ES2949159T3 (es) 2023-09-26
NZ603829A (en) 2015-03-27
BR112012028306A2 (pt) 2020-11-03
EP4234698A3 (en) 2023-11-08
US9428583B2 (en) 2016-08-30
US20200377603A1 (en) 2020-12-03
HK1258029A1 (zh) 2019-11-01
JP2020114210A (ja) 2020-07-30
JP2018065843A (ja) 2018-04-26
EP3345926B1 (en) 2023-04-05
SG185416A1 (en) 2012-12-28
AU2014224144A1 (en) 2014-10-02
EP2566892B1 (en) 2017-12-20
CN103038258B (zh) 2017-02-15
ZA201208221B (en) 2013-07-31
GT201200297A (es) 2014-10-13
CN103038258A (zh) 2013-04-10
MX2012012928A (es) 2013-05-01
CA2798432A1 (en) 2011-11-10
JP2013527762A (ja) 2013-07-04

Similar Documents

Publication Publication Date Title
CL2012003094A1 (es) Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.
CY1121934T1 (el) Αντισωματα anti-fcrn
CL2013000369A1 (es) Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2014002750A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CY1122978T1 (el) Αντισωματα εναντι-vla-4
CO7250445A2 (es) Proteínas de unión a antígeno st2
PE20160528A1 (es) Anticuerpos
CR20120371A (es) Antagonistas de pcsk9
CL2013000843A1 (es) Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
UA117364C2 (uk) Похідні аматоксину
CL2014000400A1 (es) Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
CL2011002482A1 (es) Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
CL2014000590A1 (es) Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia.
CL2011002756A1 (es) Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad.
EA201171494A1 (ru) Миметики белка smac
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
CL2012002416A1 (es) Proteina de union capaz de unirse a dll4; construccion de anticuerpo que comprende dicha proteina; conjugado de anticuerpo; acido nucleico, vector y celula huesped que comprenden el anticuerpo; composicion para la liberacion de una proteina de union; metodo para reducir la actividad del dll4 humano.
BR112012013876A2 (pt) proteínas de ligação do antígeno humano que ligam o seu b-klotho, receptores de fgf e seus complexos
CL2014000699A1 (es) Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco.
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
CL2009000567A1 (es) Anticuerpo monoclonal que enlaza especificamente tyrp1 humano; fragmento de cualquiera de los anticuerpos antes indicado; acido nucleico que codifica en anticuerpo o fragmento; vector de expresion; celula recombinante; uso del anticuerpo o fragmento para tratar cancer.
CL2011000931A1 (es) Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.